Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma
Enduring responses were reported among patients with relapsed/refractory multiple myeloma who received anitocabtagene autoleucel (anito-cel), according to findings from the phase 2 iMMagine-1 trial (NCT05396885) presented at the 2024 American Society …